Takeda Pharmaceutical Co Ltd: Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing, dated February 4, 2021, presents the Summary of Financial Statements for Takeda Pharmaceutical Company Limited for the nine-month period ended December 31, 2020 (April 1 to December 31, 2020). The company operates globally with core therapeutic areas in Gastroenterology, Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience. Financial results are reported under International Financial Reporting Standards (IFRS).
Key Financial Metrics
| Metric | 9 Months Ended Dec 31, 2020 | 9 Months Ended Dec 31, 2019 | Change (%) |
|---|---|---|---|
| Revenue | 2,427.5 Billion JPY | 2,519.5 Billion JPY | (3.6%) |
| Operating Profit | 358.7 Billion JPY | 162.5 Billion JPY | 120.7% |
| Profit Before Tax | 235.4 Billion JPY | 56.0 Billion JPY | 320.2% |
| Net Profit (Period) | 179.0 Billion JPY | 42.7 Billion JPY | 319.0% |
| Net Profit (Attributable to Owners) | 178.9 Billion JPY | 42.5 Billion JPY | 320.8% |
| Basic EPS | 114.57 JPY | 27.31 JPY | 319.5% |
| Core Operating Profit | 780.6 Billion JPY | 792.2 Billion JPY | (1.5%) |
| Core EPS | 333 JPY | 360 JPY | (7.5%) |
| Total Assets | 12,286.1 Billion JPY | 12,821.1 Billion JPY | (4.2%) |
| Total Equity | 4,639.4 Billion JPY | 4,727.5 Billion JPY | (1.9%) |
| Cash & Equivalents | 617.6 Billion JPY | 637.6 Billion JPY | (3.1%) |
| Net Cash from Operating Activities | 610.0 Billion JPY | 484.3 Billion JPY | 26.0% |
Debt and Liquidity: Total Bonds and Loans decreased to 4,751.0 Billion JPY (from 5,093.3 Billion JPY) due to repayments and redemptions. Cash and cash equivalents stood at 617.6 Billion JPY. The company maintains a strong liquidity position with no material funding issues anticipated.
Material Changes vs. Prior Period
- Profit Surge: Reported Net Profit increased by 319.0% primarily due to a 60.2 Billion JPY gain from the release of the obligation to divest the SHP647 pipeline compound and a 37.2 Billion JPY gain from the sale of non-core assets. Additionally, the prior year included a 15.6 Billion JPY impairment charge for the TAK-616 AMR program which did not recur.
- Revenue Decline: Reported revenue fell 3.6% due to foreign exchange headwinds (approx. 2.6% impact) and divestitures. On an underlying basis (constant currency, excluding divestitures), revenue grew 1.1%.
- Cost Reductions: Cost of Sales decreased 12.0% largely due to a 99.3 Billion JPY reduction in non-cash charges related to the Shire acquisition inventory step-up. SG&A expenses dropped 9.9% due to Shire integration synergies and reduced travel/event spending from COVID-19.
- Therapeutic Area Performance:
- Gastroenterology: Revenue up 10.4%, driven by ENTYVIO (+21.2%) and TAKECAB (+15.2%).
- Rare Diseases: Revenue down 8.0%, impacted by competitive pressure in hemophilia (ADVATE down 21.1%) and the NATPARA recall. However, Hereditary Angioedema (HAE) grew 13.1% driven by TAKHZYRO.
- Oncology: Flat growth (+0.2%), with NINLARO (+16.9%) and ADCETRIS (+12.5%) offsetting declines in off-patent VELCADE (-16.4%).
- Neuroscience: Revenue down 4.7%, affected by generic competition (REMINYL) and reduced patient visits due to COVID-19.
Guidance, Outlook, and Risks
Full Year 2020 Forecast (Revised Feb 4, 2021):
- Revenue: 3,200 Billion JPY (Unchanged).
- Operating Profit: 434 Billion JPY (Unchanged).
- Net Profit (Attributable to Owners): Revised upward to 180.5 Billion JPY (from 124.0 Billion JPY), a 45.6% increase, driven by updated tax rate assumptions.
- EPS: Revised upward to 115.56 JPY (from 79.39 JPY).
- Core Operating Profit: 984 Billion JPY (Unchanged).
Management Guidance: Remains unchanged with expectations for low-single-digit underlying revenue growth, high-single-digit underlying core operating profit growth, low-30s% underlying core operating profit margin, and low-teen underlying core EPS growth.
Risks and Contingencies:
- COVID-19: While the overall financial impact was deemed immaterial for the nine-month period, the company notes risks of future disruptions to clinical trials, supply chains, and patient visits if pandemic waves persist. However, oral administration profiles of some products (e.g., NINLARO) provided a relative advantage.
- Divestitures: The company is proceeding with the divestiture of Takeda Consumer Healthcare Company Limited (TCHC) to Blackstone, expected to close by March 31, 2021. A pre-tax gain of approx. 140 Billion JPY is anticipated but excluded from the current forecast due to timing uncertainty.
- Foreign Exchange: Fluctuations in currency rates remain a significant variable affecting reported results.
Investor Verification Checklist
- Non-IFRS Reconciliations: Verify the adjustments made to calculate "Underlying" and "Core" metrics, specifically the exclusion of Shire integration costs, purchase accounting effects, and the SHP647 gain.
- TCHC Divestiture Timing: Monitor the closing date of the Takeda Consumer Healthcare sale to Blackstone to determine when the anticipated 140 Billion JPY gain will be recognized.
- Product Lifecycle Management: Assess the long-term impact of generic erosion on key products like VELCADE, ADVATE, and REMINYL versus the growth trajectory of new launches like TAKHZYRO and ENTYVIO.
- Tax Rate Assumptions: Review the specific tax rate assumptions used in the revised net profit forecast, as this was the primary driver for the significant upward revision in EPS.
- Cash Flow Sustainability: Confirm that the strong operating cash flow (610 Billion JPY) supports the aggressive debt repayment strategy and dividend policy (projected 180 JPY/year).